Want to join the conversation?
New Jersey-based company $CELG said it continues to advance high potential pipeline programs to diversify opportunities. The company stated that based on interim overall survival analysis of the REMARC study, testing REVLIMID as maintenance therapy for patients with diffuse large B-cell lymphoma, $CELG will not seek approval for this indication.
$TWTR mentions Snap as one of its fiercest rivals in its 10K filing. Great head start for Snap ahead of IPO!